Page last updated: 2024-11-04

mephenesin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mephenesin is a muscle relaxant that was originally developed in the 1940s. It is believed to work by reducing the activity of nerve cells in the spinal cord. Mephenesin is typically used to treat muscle spasms, pain, and stiffness. It is not typically used as a primary treatment for chronic pain conditions. It is important to note that mephenesin can have serious side effects, including drowsiness, dizziness, and weakness. It is important to speak with your doctor before taking mephenesin. Mephenesin is studied for its potential to treat various conditions, such as muscle spasms, pain, and stiffness. Research is also being conducted to explore its potential use in the treatment of other conditions, such as seizures and anxiety. Mephenesin is a relatively safe drug when used as directed, but it can have serious side effects if it is not used properly. Mephenesin is not a cure for any disease or condition, but it can help to manage symptoms.'

Mephenesin: A centrally acting muscle relaxant with a short duration of action. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-(2-methylphenyl)glycerol : A glycerol ether in which a single 2-methylphenyl group is attached at position 1 of glycerol via an ether linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Prolaxgenus[no description available]OrchidaceaeA plant family of the order Asparagales. All members of the orchid family have the same bilaterally symmetrical flower structure, with three sepals, but the flowers vary greatly in color and shape.[MeSH]

Cross-References

ID SourceID
PubMed CID4059
CHEMBL ID229128
CHEBI ID94398
SCHEMBL ID25448
MeSH IDM0013429

Synonyms (260)

Synonym
nephelor
tolsil
kinavosyl
relaxant
rhex regulans
myanil
3-(o-tolyloxy)propane-1,2-diol
curythan
torulox
relaxar
tolofren
spartoloxyn
59-47-2
anatensin
tolulox
3-(o-tolyloxy)-1,2-propanediol
3-(2-methylphenoxy)-1,2-propanediol
mephosal
walco-nesin
curarythan
temian
myoten
prolaxin
daserd
o-cresyl glycerol ether
avoxyl
3-o-toloxy-1,2-propanediol
glykresin
seconesinz
toloxyn
myanesin
rp 3602
wln: q1yq1or b1
curaril
3-(2-tolyloxy)-1,2-propanediol
spartoloxin
glukresin
xeral
relaxyl
tolhart
tolansin
memphenesin
spasmolyn
cresoxypropanediol
myopen
tolserol
mephenesin
myolysin
avesyl
mefenesina
ortol
tolseron
tolsin
a 1141
sinan
myopna
lissephen
glyotol
moctynol
mephson
cresossidiolo
mycocuran
myasin
mephensin
1,2-dihydroxy-3-(2-methylphenoxy)propane
1-o-tolylglycerol ether
tolax
mervaldin
mianesina
tolbart
mephenesine
mephelor
avoxil
kresoxypropandiol
myoserol
stilalgin
cresossipropandiolo
o-cresol glyceryl ether
myocuran
nsc8134
thoxidil
findolar
dioloxol
anxine
daserol
1, 3-(2-methylphenoxy)-
1, 3-(o-tolyloxy)-
myoxane
myastenin
mephedan
cresodiol
saserol
byk-m 1
o-kresol-glycerinaether
myopan
myosera
myolax
cresoxydiol
tolulexin
noctynol
tolydrin
tolcil
myoxyl
mephate
diloxol
proloxin
avosyl
decontractil
myanol
oranixon
nsc-8134
myodetensine
sansdolor
halabar
o-cresyl .alpha.-glyceryl ether
dioloxal
.alpha.,.beta.-dihydroxy-.gamma.-(2-methylphenoxy)propane
renarcol
rhex 'hobeino'
mepherol
thioxidil
sq 1156
atensin
bdh 312
mephesin
findolor
prolax
tokerol
.alpha.-(o-tolyl)glyceryl ether
tolyspaz
walconesin
lissenphan
tolosate
mc 2303
walko-nesin
miolisina
tolynol
mefensina
relaxil
rex regulans
glytol
mephin
3-(o-methylphenoxy)-1,2-propanediol
nembusen
glyceryl o-tolyl ether
myodetensin
decontractyl
component of tolagesic
1,2-propanediol, 3-(2-methylphenoxy)-
nsc-50788
nsc50788
nsc-36140
nsc36140
nsc25234
nsc-25234
DIVK1C_000076
KBIO1_000076
3-[(2-methylphenyl)oxy]propane-1,2-diol
tolserol (tn)
mephenesin (inn)
D02595
SPECTRUM_001402
PRESTWICK2_000178
PRESTWICK_577
cas-59-47-2
IDI1_000076
3-(2-methylphenoxy)propane-1,2-diol
PRESTWICK3_000178
BPBIO1_000083
einecs 200-427-4
alpha-(o-tolyl)glyceryl ether
mephenesine [inn-french]
mephenesinum [inn-latin]
1-ortho-tolylglycerol ether
1,2-propanediol, 3-(o-tolyloxy)-
brn 2047373
nsc 25234
o-kresol-glycerinaether [german]
ageflex cge
alpha,beta-dihydroxy-gamma-(2-methylphenoxy)propane
mefenesina [inn-spanish]
o-cresyl alpha-glyceryl ether
AB00052216
mephenesin, 98%
NCGC00094908-01
NCGC00094908-02
KBIO2_004450
KBIOGR_001473
KBIOSS_001882
KBIO2_001882
KBIO3_001856
KBIO2_007018
PRESTWICK1_000178
SPECTRUM2_001418
SPECTRUM4_001007
NINDS_000076
PRESTWICK0_000178
SPBIO_001996
SPECTRUM3_000908
SPBIO_001496
SPECTRUM1501140
SPECTRUM5_001199
BSPBIO_000075
NCGC00094908-03
HMS2092F17
CHEMBL229128
HMS500D18
HMS1921J09
HMS1568D17
HMS2095D17
mephenesin [inn:ban:nf]
unii-7b8pir2954
7b8pir2954 ,
mephenesinum
nsc-757857
nsc757857
pharmakon1600-01501140
dtxcid803254
tox21_111356
dtxsid4023254 ,
CCG-38970
FT-0628209
AKOS015912866
S5032
BRD-A55469827-001-01-7
mephenesin [who-dd]
mephenesin [inn]
mephenesin [mart.]
mephenesin [mi]
SCHEMBL25448
tox21_111356_1
NCGC00094908-06
CS-5340
HY-B1283
STL430456
(.+/-.)-mephenesin
JWDYCNIAQWPBHD-UHFFFAOYSA-N
rhex
(s)-3-(2-methylphenoxy)propane-1,2-diol
AB00052216_04
CHEBI:94398
1-(2-methylphenyl)glycerol
1-(2-tolyl)glycerol
1-(o-tolyl)glycerol
mfcd00004718
SR-05000001772-3
sr-05000001772
SR-05000001772-2
SR-05000001772-1
glycerol-1-(o-tolyl) ether
SBI-0051654.P002
HMS3712D17
M3076
Q3333250
DB13583
HMS3886K09
D97581
1,2-propanediol, 3-(2-methylphenoxy)
A923330
EN300-7408655

Research Excerpts

Overview

Mephenesin is a muscle relaxant with poorly documented clinical value. It is mostly applied locally in trauma.

ExcerptReferenceRelevance
"Mephenesin is a muscle relaxant with poorly documented clinical value. "( Mephenesin: abuse and dependence.
, 2013
)
3.28
"Mephenesin is a muscle relaxant, mostly applied locally in trauma. "( [Severe contact dermatitis caused by mephenesin].
Bachmeyer, C; Blum, L; Cabane, J; Duriez, P; Fléchet, ML; Imbert, JC, 1996
)
2.01

Bioavailability

ExcerptReferenceRelevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The dose-response relationships for strychnine and picrotoxin were investigated at fixed pressures."( Investigations into the origin of the high pressure neurological syndrome: the interaction between pressure, strychnine and 1,2-propandiols in the mouse.
Bowser-Riley, F; Daniels, S; Smith, EB, 1988
)
0.27
" In therapeutic dosage of 6 to 12 mg."( The sublingual administration of curare.
MAYER, H; NEFF, WB, 1953
)
0.23
" An increase of the dosage and, correspondingly, the total inhibition of SPMA is accompanied by reduction of the slow-wave components from the pattern of cardiac and respiratory rhythms."( [CHANGE OF CHARACTER OF INTERSYSTEMIC INTERACTIONS IN NEWBORN RAT PUPS UNDER CONDITIONS OF A DECREASE OF MOTOR ACTIVITY].
Dmitrieva, LE; Kuznetsov, SV; Sizonov, VA,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
glycerol etherAny ether having glyceryl as at least one of the O-substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.02370.006038.004119,952.5996AID1159521
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.70900.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency23.80060.000229.305416,493.5996AID743075; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency10.96400.00108.379861.1304AID1645840
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.00070.023723.228263.5986AID743222
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (51)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1145382n-octanol-water partition coefficient, log P of the compound1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Quantitative structure-activity relationships. 1. The modified Free-Wilson approach.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID754208Neuroprotective activity in Sprague-Dawley rat DRG neurons assessed as enhancement of neurite outgrowth at 0.01 to 1 uM after 24 hrs by confocal microscopic analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Guaifenesin derivatives promote neurite outgrowth and protect diabetic mice from neuropathy.
AID287370Half life of hydrolysis in phosphate buffer at pH 7.42007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
The synthesis of amphipathic prodrugs of 1,2-diol drugs with saccharide conjugates by high regioselective enzymatic protocol.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1145379Antifungal activity against Trichophyton mentagrophytes assessed as growth inhibition measured for 14 days by tube dilution method1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Quantitative structure-activity relationships. 1. The modified Free-Wilson approach.
AID287369Half life of hydrolysis in hydrochloric acid buffer at pH 1.22007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
The synthesis of amphipathic prodrugs of 1,2-diol drugs with saccharide conjugates by high regioselective enzymatic protocol.
AID287368Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
The synthesis of amphipathic prodrugs of 1,2-diol drugs with saccharide conjugates by high regioselective enzymatic protocol.
AID287367Distribution coefficient, log D at pH 7.42007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
The synthesis of amphipathic prodrugs of 1,2-diol drugs with saccharide conjugates by high regioselective enzymatic protocol.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (530)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990483 (91.13)18.7374
1990's14 (2.64)18.2507
2000's4 (0.75)29.6817
2010's22 (4.15)24.3611
2020's7 (1.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.18 (24.57)
Research Supply Index6.35 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index87.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.35%)5.53%
Reviews14 (2.45%)6.00%
Case Studies15 (2.63%)4.05%
Observational0 (0.00%)0.25%
Other540 (94.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]